IAM Trade Secrets
News & Analysis
- - - Categories
    - News & Analysis
    - Long Reads
    - Opinion
  - - Topics
    - Copyright, designs & trademarks
    - Finance & valuation
    - FRAND/SEPs
    - Law & policy
    - Licensing
    - Litigation
    - Transactions
  - - Regions
    - Africa & Middle East
    - Asia-Pacific
    - Europe
    - Latin America & Caribbean
    - North America
Reports
- - - Reports
    - Special Reports
    - Panel Reports
    - Reports Centre
Data & Tools
- - - Data
    - Patent 1000 Analytics
    - Data Analysis
    - Data Hub
  - - Tools
    - GTDT
Rankings
- - - IAM Patent 1000
    - Introduction
    - All Firms
    - All Individuals
  - - IAM Strategy 300
    - Introduction
    - All individuals
  - - Global Leaders
    - IAM Global Leaders
    - Strategy 300 Global Leaders
  - - IAM Analytics
    - Patent 1000 Analytics
Insight
- - - Insight
    - Guides
    - Reviews
    - Market Insight
  - - Hub
    - SEP/FRAND
Events
- - - Events
    - IAM & IPBC events
    - Diary
IAM Market
- Visit WTR
- About
- Archive
Login | Register
Subscribe Now

Home
Organisation: Vertex Pharmaceuticals

Organisation: Vertex Pharmaceuticals

Historic CRISPR drug approval heralds new era in Cas9 IP wars

Green light for first ever Cas9 therapy ushers in next phase of licensing and litigation efforts.

17 November 2023

Unlock unlimited access to all IAM content